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Abstract
Background: Hepatitis C viral (HCV) infection is a significant public health problem. In the UK,
an estimated 200,000 individuals have active HCV infection, most of whom are injecting drug users
(IDUs). Many IDUs spend time within the prison system therefore screening for HCV infection in
this setting is important. However, uptake of testing within prisons is very low.
Methods: Qualitative interview study. 30 interviews with 25 male and 5 female prisoners with a
history of injecting drug use.
Results: Personal and institutional barriers to uptake of testing for HCV were identified. Personal
barriers included: prisoners' fears and lack of knowledge about HCV, low motivation for testing,
lack of awareness about the testing procedure, and concerns about confidentiality and stigma.
Institutional barriers included: the prisons' applications procedure for testing, inadequate pre- and
post-test discussion, lack of pro-active approaches to offering testing, and lack of continuity of care
on discharge and transfer.
Conclusion: This study highlights potential areas of development in the management of HCV in
prisons. Further research is needed to evaluate care pathways for HCV in the prison setting and
to develop and assess interventions to improve the uptake of testing for HCV by prisoners.
Background
Hepatitis C viral (HCV) infection is a significant public
health problem. Chronic infection, if left untreated, can
lead to serious illness in the long-term such as cirrhosis
and cancer of the liver. In England, the estimated preva-
lence of active HCV infection is 0.4%, equating to
200,000 cases[1]. The overwhelming burden of disease is
associated with injecting drug use (IDU), which is identi-
fied as a risk factor in over 80% of cases[2]. Amongst
IDUs, HCV prevalence rates of 40–80% have been
reported[3,4]. The custodial setting has a high proportion
of prisoners with a history of IDU; estimated at around
24%[5]. Up to 61% of IDUs have spent time within the
prison system[4].
The Hepatitis C Strategy for England, 2002, encourages
testing for HCV in high risk populations[1]. There is good
evidence that selective testing for HCV in IDUs, is effective
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in the long-term[6]. A recent study demonstrated the cost-
effectiveness of screening for HCV in the prison popula-
tion[7]. Whilst in prison, IDUs lead a less chaotic life than
they would in the community. Hence, the prison setting is
an important environment to offer health promotion and
treatment interventions.
Although HCV testing is available in the prison healthcare
system, the uptake of such opportunities is low; Skipper et
al reported an uptake rate amongst prisoners of only
8.5%[8]. The reasons for this low uptake are not known.
The purpose of this study was to identify the factors that
influence the uptake of testing for HCV infection by pris-
oners. Knowledge of these barriers will help to optimise
the ways in which testing opportunities are made availa-
ble to prisoners.
Methods
This was a qualitative study using audio-recorded semi-
structured interviews in a sample of purposively selected
prisoners. Participants were recruited from three prisons
in Northeast England: HMP Durham; HMP Frankland
and HMP Low Newton (Table 1). Prisoners were eligible
if they were aged 18 years or over, had injected drugs in
the past and were able to communicate in English. At
HMP Frankland prisoners with a history of injecting drug
use were identified from referrals to the Counselling,
Assessment, Referral, Advice and Throughcare Service
(CARATS). Eligible participants at HMP Durham were
identified from referrals to the detoxification service. At
HMP Low Newton participants were identified from data
obtained from the Grubin Tool health assessment com-
pleted on reception.
The interview schedule was developed through consulta-
tion with a project steering group, comprising prison
healthcare staff, specialists in communicable disease con-
trol, and representatives from Primary Care Trusts and
Drug and Alcohol Action Teams. Prisoners were provided
with information sheets about the study and asked to give
written consent to participate in the study prior to inter-
view. Information and consent documents made clear
that participation or non-participation in the study would
not prejudice nor enhance their treatment in the prison.
No reimbursement or inducements were offered to pris-
oners.
All prisoners were interviewed by LS in the health care
facility at each establishment. LS was accompanied by a
CARATS worker who acted as advocate for the prisoner.
Interviews lasted between 10 and 40 minutes. All inter-
views were audio-recorded (with the prisoner's consent),
transcribed, and then checked for accuracy against the
recording. The research team (LS, MJM, FMK) analysed
transcripts using established procedures of constant com-
parative analysis[9] from which themes were developed
from the participants' responses.
The study was reviewed and given a favourable opinion by
the Northern and Yorkshire Multi-centre Research Ethics
Committee (MREC number: 04MRE0384). The study was
approved by the Prisons Research Applications and Ethics
Panel (PRAEP).
Results
Ninety-nine eligible prisoners were identified. Fifty-five
declined to participate. Forty-four initially agreed to par-
ticipate but of these 10 declined to participate on the day,
three were transferred to another institution prior to inter-
view and one was held in a segregation unit during the
available interview period. 30 prisoners took part in the
study; 25 male and five female. Table 2 demonstrates that
19 participants had already taken up opportunities for
HCV testing, most whilst in the prison system.
Interviews identified personal and institutional barriers to
the uptake of testing for HCV. Personal barriers related
predominantly to lack of knowledge and fear of disease, a
lack of awareness about the testing procedure, disease
prognosis, treatment and outcome, and concern about
confidentiality and stigma. Motivation was a personal fac-
tor that could facilitate uptake of testing. Institutional bar-
riers related to the application to request a test,
inadequate pre- and post- test discussion, and lack of con-
tinuity of care in the event of discharge or transfer from
prison.
Table 1: Characteristics of participating prisons
Prison Geographic area Gender of inmates Typical duration of stay Category* Capacity
HMP Durham Local Male Short B 919
HMP Frankland National Male Long A 720
HMP YOI Low Newton Local Female Short A 396
* A Category A Prison is a maximum security prison, highly secured, and used mainly for high risk offenders, whose escape would be highly 
dangerous to the public or the police or the security of the state, no matter how unlikely that escape might be, and for whom the aim must be to 
make escape impossible. A Category B Prison is for prisoners for whom the very highest conditions of security are not necessary, but for whom 
escape must be made very difficult [15]BMC Public Health 2007, 7:98 http://www.biomedcentral.com/1471-2458/7/98
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'Cause they're maybes scared, scared of knowing'
Ignorance and fear of disease was common amongst par-
ticipants. Many were not aware of disease prognosis, treat-
ment options and outcomes. Some assumed that a
positive diagnosis was a 'death sentence' (See Geoff, Table
3).
HCV was often conflated or formed a constellation with
other blood borne viruses such as HIV. There was confu-
sion about mode of transmission and likely prognosis
(See Andy, Table 3).
Perception of risk was mixed. Some prisoners attached
great significance to sexual promiscuity whilst others,
although recognising the dangers of sharing needles and
syringes, did not always appreciate the risks involved in
sharing other paraphernalia (See Danny, Table 3).
'You bear a responsibility not to pass it on'
The main motivations for testing were discussed in terms
of social or personal responsibility. Some of those who
had had the test were unaware of potential treatments but
had undertaken the test to determine whether they
needed to take action to avoid infecting others (See
Emma(a), Table 3).
'They couldn't get any blood out of me'
Some prisoners complained that health care personnel
lacked the skills required to take venous blood; although
some acknowledged that the poor state of their veins con-
tributed to poor venous access. Several prisoners had had
to take their own blood because nursing or medical staff
were unable to do so. (See Chrissie, Table 3)
Prisoners were not usually aware of how the test would be
carried out, but this did not appear to be a barrier in itself.
Most of those who were aware that testing would involve
venepuncture felt that prisoners were not likely to be
frightened of needles. Prisoners were not aware of the
availability of a buccal swab or finger-prick blood-test.
'You don't want the whole wing to know'
There were concerns that confidentiality would not be
maintained after accessing healthcare. These concerns
Table 3: Personal barriers
GEOFF: Er, I don't know really, [pause] er, I don't really know, I mean, I think like I say, I think people are just frightened ye na [you know]. People 
are frightened to get the test ye na [you know], thinking that it could be a killer not knowing what, not knowing what it actually is, what it actually 
does to you, I mean?
ANDY: When I hear people on about it, it's, it kills you and that's it, (Uh hm) when you get it that's it. There's no way of getting rid of it, you've got 
it for life (Uh hm) and all the rest of it. Which, isn't quite true. I mean you can have it for the rest of your life, but you can clear it (Uh hm). There is 
like you say treatments available where you can get rid of it.
DANNY: Em, like I thought Hepatitis could live out of the body, certain Hepatitis's, but that some can't and some can. And the ones that I thought 
could, couldn't.. Things like that and I thought you could catch Hepatitis from like using towels and stuff but you can't.
EMMA(a): 'Cause I've got, there's no way I'm not having no, even if it was a one per cent chance of passing it down to me bairn [child] I wouldn't 
have it... Me bairn's done nowt [nothing], so it didn't ask to be born... to a junkie mother.
CHRISSIE: I had to, I had to do well most of it meself, with 'em I had to help because they couldn't get vein do you know what I mean? I had to have 
a go myself to try and get them something do you know?
TONY: I, the way I would think of it is more private. More privacy round it. Because there's a lot of people don't want to know they've got it 
because when you've got to put your sheets in and all that, you come down here with twenty, thirty other people and they're all what ye here for 
and all the rest of it.
EMMA(b): There was a lass with Hep C on Landing 2 and it was "Heppie" and that they call her, do you know what I mean? Yeah. Not very nice.
GARY: Well I know that it's contracted through blood ..., er it's very rare em and you can catch it through intercourse, sexual intercourse er, 
there's not many people that have, and the people that say that they have, I generally don't believe. I think they're just too embarrassed to say that 
they've been injecting drugs
Table 2: Uptake of testing opportunities by study participants
Prison (total participants) Testing status Venue of testing* No. with a positive test result
HMP Durham (12) 9 tested Prison 5 2
1 applied, 1 unsure, 1 declined Hospital 4
GP practice 1
Needle exchange 1
HMP Frankland (13) 8 tested Prison 6 4 
2 applied, 3 declined Hospital 1
Not stated 1
HMP YOI Low Newton (5) 2 tested Prison 2 1 
2 applied, 1 unknown
* Some participants had multiple testsBMC Public Health 2007, 7:98 http://www.biomedcentral.com/1471-2458/7/98
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were related to a fear of stigmatisation. Prisoners were
concerned about the level of detail that they had to pro-
vide to apply for a test and about who might have access
to these details (see Tony, Table 3).
The problem of stigmatisation was related to IDU and
HCV infection (see Emma(b), Table 3). Prisoners were
concerned that they may be stigmatised if there was a large
bruise resulting from failed attempts at venepuncture,
which would then be apparent to other prisoners and
prison officers. Prisoners were more likely to attribute
HCV infection to sexual promiscuity rather than to IDU
(see Gary, Table 3).
'You have to put an app in. An app!!'
Prisoners were required to complete an application form
('app') for access to health care, including HCV testing.
Many prisoners regarded the 'app' as unnecessarily
bureaucratic and a barrier to testing in terms of a require-
ment to disclose IDU and the long waiting time (see Ali-
son, Table 4). One prisoner had made three applications
for a test and had not been tested.
'I think someone should be there to talk to you about it... 
he didn't tell us nowt [nothing]"
Although some prisoners reported that they had had the
opportunity for pre- and post-test discussion with a
healthcare professional, this was not always the case (see
Emma, Table 4). In some cases test results were 'posted' to
prisoners under their cell door without post-test informa-
tion and discussion. Several prisoners, like Emma, com-
pared the availability of 'counselling' with that provided
before and after HIV testing and thought that the proce-
dure was more robust for HIV than for HCV.
'I was just trying to get through my rattle [detox]. That's 
all I were thinking about'
The offer of testing opportunities may not arise at an
appropriate time. Prisoners with short sentences or who
are on remand (ie. awaiting trial) might not be able to
keep their appointments for testing because of court
appearances or early discharge. Some prisoners could not
recall whether they had been offered a test because they
had other priorities at first reception to prison or because
they were suffering the effects of drug/alcohol withdrawal
at the time (see Chrissie, Table 4).
'I got shipped out, so it never really happened'
Prisoners felt that there was not always adequate commu-
nication and transfer of information between prisons or
between prisons and healthcare in the community. A pris-
oner, waiting for the test in one prison prior to transfer,
would have to re-apply at the new prison. Two prisoners
changed their minds about testing and had not reapplied
after transfer as they would have to wait. Other prisoners
were concerned that treatments or interventions initiated
in the community would not be followed up in prison
(see Jimmy, Table 4).
'in here you wait like you wouldn't in the community'
Some prisoners felt that they might not have the same
access to healthcare for Hepatitis C whilst in prison as they
would do in the community (see Colin, Table 4). Others
believed that poor access to healthcare was encountered
Table 4: Institutional barriers
ALISON: That's the thing when you have to put all these applications in, (Ah ha) it puts you off.... It's because you, everything you do you've got, it's 
always put an application in, put an ap. in, and people are like "What, I have to put an app. in just to get to see if I've got a disease?" Do you know 
what I mean, that's the way people think. When you've got to put an app. in it's like I'll do it later, do you know what I mean? .... And it just, it's a 
nightmare, them apps. are definitely.
EMMA: I was tested... last year and I, I didn't have [Hep C], and I come back [to prison] and a certain doctor said that he would take bloods and 
everything. He took bloods off us and then I had to go and see him on Monday and he said "You've got Hepatitis virus in your body" and em, he said 
"You need more blood tests" and he took them, he took loads of blood off us and then he put these big stickers on saying what you call, infection 
and then diseases do you know what I mean, I felt stupid. And he says "Right, come and see us next Monday" and that was it. I was crying me eyes 
out. But he didn't, he didn't tell us nowt.
CHRISSIE: Yeah because like I'm, honest when I was rattling I was dead weak and I couldn't even remember I was just trying to get through my 
rattle. That's all I were thinking about.
JIMMY: they gave us a vaccination, then gave us another one, then I got me booster, but in the meantime while I was still using they wanted to take 
me blood afterwards to make sure if I had caught anything in the meantime (Yeah) but I ended up in prison (Right) so I couldn't get me blood taken.
COLIN: What I'm led to believe is we get the same as what you get in the community like you know so that's what we're told like. But er, I 
wouldn't know like I've been in a long time, but really I think, I don't think it's right. ... I think health care, I think you should have in, you know in an 
emergency then, in here you wait like you wouldn't in the community, but you wouldn't if it was an emergency in the community like you wouldn't 
wait like you know, and er, that's what I think.
DANNY: At the end of the day it's [Hep C] sort of, it's self inflicted isn't it? ... And we [IDUs] are just a society who, who people aren't really 
bothered about.
LS: Well, if you'd still been outside, would you have gone to your GP and asked for testing?
DANNY: Well I was, I did approach my GP and he referred us to the consultant but like I said it's been adjourned twice and I think that would've 
happened all the time, and they would've just got sick of us. ... Uh hm. They would've just got sick and said look, there's people there who really 
want it, wanting to do the treatment and you're just messing about by not staying off drugs.BMC Public Health 2007, 7:98 http://www.biomedcentral.com/1471-2458/7/98
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in prison and in the community because of stigma relating
to IDU (see Danny, Table 4).
Discussion
This project has identified personal and institutional bar-
riers in participants' discourse that could explain the poor
uptake of testing for HCV by prisoners. Personal barriers
included: prisoners' fears and lack of knowledge about
HCV, lack of awareness about the test procedure, and con-
cerns about confidentiality and stigma. Institutional bar-
riers included: the prisons' applications procedure for
testing, inadequate pre- and post-test discussion, lack of
appropriate approaches to offering testing, and lack of
continuity of care on discharge and transfer.
There are many benefits in the early diagnosis of HCV
infection: Knowledge of the status of HCV infection may
reduce risk behaviour[11,12]; anti-viral treatment can
eradicate infection in 40–85% of cases depending on viral
genotype[13]; secondary preventive measures, such as
reducing alcohol intake, can reduce the risk of developing
hepatocellular carcinoma[14]; and the need for other
health protection interventions, such as Hepatitis B and
Hepatitis A vaccination may be identified. Yet, the major-
ity of those with HCV infection remain undiagnosed; in
England, fewer than 20% of those infected are diag-
nosed[1].
This study is not unique in identifying a poor understand-
ing of HCV infection amongst IDUs[10]. It is possible that
increasing the awareness of the disease and the benefits of
diagnosis will increase the uptake of testing.
We know that the uptake of testing for HCV by prisoners
is low and that there is a higher prevalence of HCV
amongst the prison population because of the higher pro-
portion of injecting drug users in the custodial environ-
ment. This study demonstrates that: personal and
institutional barriers may adversely affect the uptake of
testing for HCV in prisons; there is general lack of aware-
ness and fear of HCV amongst prisoners with a history of
injecting drug use; prisoners are concerned about the
potential for breaches in clinical confidentiality and about
the stigma associated with a diagnosis of HCV. These find-
ings will enable development of interventions to improve
the uptake of testing for HCV in prisons and to develop
care pathways that provide seamless healthcare within
and outside the custodial setting.
Limitations of this study
Participants were recruited from three prisons with repre-
sentation from male and female prisoners, and long-stay
and short-stay establishments. However, only five women
prisoners were interviewed, none from long-stay prisons.
Although there is a potential for bias because data satura-
tion was not reached amongst female participants, never-
theless, the interviews elicited a wide spectrum of opinion
and experience. The presence of CARATs worker may have
influenced the content and level of detail of the inter-
views. However, it appeared that prisoners were comfort-
able with the presence of the CARATs worker and in most
cases appeared to have already established a degree of rap-
port with either an individual officer or the CARATs team
in general.
One key limit to the study was that we were unable,
within existing resources, to also interview prison person-
nel and health professionals working in the prisons to
ascertain their views of barriers to uptake of HCV testing.
We are therefore not able to identify potential disincen-
tives for carrying out testing, for example the impact on
resources of the potential added burden of care and treat-
ment for those diagnosed with HCV. Nonetheless, this
study is an example of effective collaborative working
between multiple stakeholder organisations. A multidisci-
plinary steering group facilitated the recruitment of partic-
ipants and conduct of the project.
Conclusion
This study has identified some factors that may contribute
to the poor uptake of HCV testing in prisons. There is a
need to develop approaches to increase the uptake of test-
ing by raising awareness amongst prisoners about HCV
infection, optimising testing pathways that support
appropriate testing at appropriate times during a pris-
oner's stay in prison, ensuring adequate pre- and post-test
discussion, and by developing care pathways for HCV that
enable seamless continuity of care.
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